Prevalence of new psychoactive substances addiction: a hospital-based cross-sectional study

Mariya Prilutskaya 1 * , Oleg Yussopov 2, Nikolay Negay 3, Kuanysh Altynbekov 3, Makpal Tokayeva 1
More Detail
1 Department of Personalized Medicine and Pediatrics, Pavlodar Branch of Semey Medical University, Pavlodar, Republic of Kazakhstan
2 Epidemiology Department, Monitoring Center on Alcohol and Drugs, Pavlodar, Republic of Kazakhstan
3 Scientific and Clinical Department, Republican Scientific and Practical Center of Mental Health, Director, Almaty, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 1, Issue 55, pp. 11-16. https://doi.org/10.23950/1812-2892-JCMK-00730
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Background: New psychoactive substances are a combined group of chemical substances developed in an attempt to circumvent control and restrictive measures for traditional drugs. Until 2017, the countries of Central Asia remained a gray spot on the maps of epidemiological new psychoactive substances reports. The largest share of new psychoactive substances on the Kazakhstani market became of a serious concern for both the law enforcement authorities and the public health services during the last five years.
Objectives: The aim of the study was to assess the proportion of hospitalizations in Kazakhstan related to new psychoactive substances addiction over a three-year period (2016-2018) and to describe the patterns of new psychoactive substances use in the sample of admitted patients.
Material and methods: This study was a retrospective, cross-sectional investigation using regional databases consisting of the 2018 cases of hospitalizations at 16 state regional mental treatment centers and 3 state narcological clinics across Kazakhstan. We analyzed 345 cases of NPS addiction.
Results: The proportion of admitted in 2018 new psychoactive substances patients amounted to 10.01% (9.1%; 11.1%), comprising an ascending trend since 2016. The highest prevalence of the new psychoactive substances addiction was registered in Nur-Sultan, Almaty cities, and North-Kazakhstan region. Cathinones prevailed over other NPS groups (71.9%) and were mostly used in parallel with traditional opioids. Synthetic cannabinoids (28.1%) were associated with herbal cannabis use in three quarters of cases; smoking absolutely prevailed as the main route of their administration.
Conclusion: This study suggests that new psychoactive substances addiction is a current clinical phenomenon, which should be reflected in the development and revision of the national drug treatment programs across Kazakhstan. The disparity of new psychoactive substances prevalence in the regions should be considered in the development of local anti-drug plans by the health care service and law enforcement authorities.

CITATION

Prilutskaya M, Yussopov O, Negay N, Altynbekov K, Tokayeva M. Prevalence of new psychoactive substances addiction: a hospital-based cross-sectional study. Journal of Clinical Medicine of Kazakhstan. 2020;1(55):11-6. https://doi.org/10.23950/1812-2892-JCMK-00730

REFERENCES

  • UNODC. February 2019 - UNODC-SMART: Almost 900 NPS reported to UNODC from 119 countries and territorieshttps://www.unodc.org/LSS/Announcement/Details/eff8dc38-7ab0-42b0-8cd9-753b89953fcc.
  • UNODC. Assessment of the situation with synthetic narcotics in Central Asia. Report of the Global SMART program. Vienna: UNODC typography. 31.
  • Prilutskaya MV, Molchanov SN. Assessment of needs in improvement of clinical competences on therapy of dependences from novel psychoactive substances in the Republic of Kazakhstan. J Clin Med Kaz. 2017; 43(1): 30-33. https://doi.org/10.23950/1812-2892-JCMK-00383
  • Yussopov O, Kazakov V, Prilutskaya M et al. National Report on Drug situation in Republic of Kazakhstan. Prague: ResAd. 2019; 276.
  • King LA, Corkery JM. An index of fatal toxicity for new psychoactive substances. J Psychopharmacol. 2018; 32(7):793-801. https://doi.org/10.1177/0269881118754709
  • Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017; 376(3):235-242. https://doi.org/10.1056/NEJMoa1610300
  • Shalit N, Barzilay R, Shoval G, et al. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study. J Clin Psychiatry. 2016; 77(8):e989-e995. https://doi.org/10.4088/JCP.15m09938
  • EMCDDA. High-risk drug use and new psychoactive substances. Rapid Communication. Luxembourg: Publications Office of the European Union, 2017; 21.
  • Pettie J, Burt A, Knipe DW, et al. New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh. Br J Clin Pharmacol. 2018; 84(10):2303-2310. https://doi.org/10.1111/bcp.13672
  • Law of the Republic of Kazakhstan. About amendments and additions to some legislative acts of the Republic of Kazakhstan on drug control issues, psychotropic substances, their analogues and precursors [in Russian]. 2018; https://online.zakon.kz/document/?doc_id=38951688 Accessed January 17, 2020.
  • Stanley JL, Mogford DV, Lawrence RJ, Lawrie SM. Use of novel psychoactive substances by inpatients on general adult psychiatric wards. BMJ Open. 2016; 6(5):e009430. https://doi.org/10.1136/bmjopen-2015-009430
  • Subeliani D, Otiashvili D, Kutelia L, et al. Patterns of use of new psychoactive substances and perceived benefits and negative effects: results of online survey in Georgia (country). Journal of Substance Use. 2019; https://doi.org/10.1080/14659891.2019.1692927
  • Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep. 2016; 18(5):52. https://doi.org/10.1007/s11920-016-0694-1
  • Banks ML, Worst TJ, Rusyniak DE, Sprague JE. Synthetic cathinones ("bath salts"). J Emerg Med. 2014; 46(5):632-642. https://doi.org/10.1016/j.jemermed.2013.11.104
  • Karila L, Megarbane B, Cottencin O, Lejoyeux M. Synthetic cathinones: a new public health problem. Curr Neuropharmacol. 2015; 13(1):12-20. https://doi.org/10.2174/1570159X13666141210224137
  • Kapitány-Fövény M, Farkas J, Pataki PA, et al. Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms. Hum Psychopharmacol. 2017; 32(3):10. https://doi.org/10.1002/hup.2602
  • Caviness CM, Tzilos G, Anderson BJ, Stein MD. Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults. Subst Abus. 2015; 36(3):368-373. https://doi.org/10.1080/08897077.2014.959151
  • Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014; 35(2):184-189. https://doi.org/10.1080/08897077.2013.846288
  • Vallersnes OM, Persett PS, Øiestad EL, Karinen R, Heyerdahl F, Hovda KE. Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway. Clin Toxicol (Phila). 2017; 55(7):636-644. https://doi.org/10.1080/15563650.2017.1312002
  • Dines AM, Wood DM, Yates C, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila). 2015; 53(9):930. https://doi.org/10.3109/15563650.2015.1088157